RayKnowChina Research Map
Shortlist

ShanghaiShanghai Jiao Tong University School of Medicine

Shanghai Ninth People's Hospital

上海交通大学医学院附属第九人民医院

Listed for 19 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Shanghai Ninth People's Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌6 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌4 papers led
  3. Stomach cancer胃癌22 papers led
  4. Retinoblastoma视网膜母细胞瘤29 papers led
  5. Osteosarcoma骨肉瘤16 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤4 papers led
  7. Neuroblastoma神经母细胞瘤1 paper led
  8. Haemophilia A血友病 A1 paper led
  9. Fanconi anaemia范可尼贫血1 paper led
  10. Takayasu arteritis大动脉炎0 papers led
  11. Idiopathic pulmonary fibrosis特发性肺纤维化4 papers led
  12. Spinal muscular atrophy脊髓性肌萎缩症0 papers led
  13. Duchenne muscular dystrophy杜氏肌营养不良2 papers led
  14. Behçet disease白塞病1 paper led
  15. IgA nephropathyIgA 肾病0 papers led
  16. Osteogenesis imperfecta成骨不全症1 paper led
  17. Hirschsprung disease先天性巨结肠0 papers led
  18. Inherited epidermolysis bullosa遗传性大疱性表皮松解症1 paper led
  19. Leber hereditary optic neuropathyLeber 遗传性视神经病变1 paper led

Not listed for: Hepatocellular carcinoma, Hepatoblastoma, Chordoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Fabry disease, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hereditary angioedema, Familial adenomatous polyposis, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 6 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
6
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 1120232024: 0020242025: 002025

10 hospitals in Shanghai for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrent / metastatic diseaseImaging & AI
Departments in papersENT / head & neck surgery

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 4 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 2220242025: 002025

18 hospitals in Shanghai for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesMolecular markers & genomics
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 22 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
22
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 4420212022: 2220222023: 6620232024: 7720242025: 332025

18 hospitals in Shanghai for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopyPeritoneal spread & advanced diseaseSurgery
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Medical oncology
Papers it led22
  1. Differential Rates of Early Gastric Cancer in the Urban and Rural Medical Centers of Hangzhou, China.2025Clinical and translational gastroenterologyFree full text
  2. Mapping immune trajectories from Helicobacter pylori gastritis to gastric cancer.2025Frontiers in immunologyFree full text
  3. Effect of food loop and duodenal stump fixation on clinical outcomes in patients undergoing radical gastrectomy with Roux-en-Y reconstruction for distal gastric cancer: a single-center propensity score matching analysis.2025Surgical endoscopyFree full text
  4. Syphilitic gastritis resembling gastric cancer.2024Gastrointestinal endoscopy
  5. A disappeared early gastric neoplasia.2024Gastrointestinal endoscopy
  6. Huang-Jin-Shuang-Shen Decoction promotes CD8+ T-cell-mediated anti-tumor immunity by regulating chemokine CXCL10 in gastric cancer.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  7. Influence of lymph node removal on the prognosis of high malignancy potential gastric gastrointestinal stromal tumors: Insights from population-based study.2024PloS oneFree full text
  8. Long-term survival outcomes of endoscopic therapy vs. surgical resection in patients with cardia gastrointestinal stromal tumor.2024PloS oneFree full text
  9. Sustained silence of a small signet ring cell carcinoma.2024Revista espanola de enfermedades digestivas
  10. Calcifying fibrous tumor and pathological analysis.2024Revista espanola de enfermedades digestivas
  11. An unusual case of gastric ulcers.2023Asian journal of surgery
  12. Overexpression of Integrin alpha V (ITGAV) in gastric cancer and its prognostic significance.2023Asian journal of surgery
  13. A rare case of gastric submucosal eminence arising from calcified fibrous tumor.2023Asian journal of surgery
  14. Pembrolizumab alone or in combination with chemotherapy versus chemotherapy for advanced gastric cancer: A cost-effectiveness analysis.2023Cancer medicineFree full text
  15. High-grade intraepithelial neoplasia of the cervical esophagus arising from a tiny ectopic gastric mucosa.2023Revista espanola de enfermedades digestivas
  16. An unusual cause of a protuberant lesion of the gastric antrum.2023Revista espanola de enfermedades digestivas
  17. An unusual protuberant lesion in the gastric body.2022Asian journal of surgery
  18. IL-6/IL-10 mRNA expression ratio in tumor tissues predicts prognosis in gastric cancer patients without distant metastasis.2022Scientific reportsFree full text
  19. Hsa-miR-30a-3p attenuates gastric adenocarcinoma proliferation and metastasis via APBB2.2021AgingFree full text
  20. Hsa_circ_0008434 regulates USP9X expression by sponging miR-6838-5p to promote gastric cancer growth, migration and invasion.2021BMC cancerFree full text
  21. Positive feedback between ROS and cis-axis of PIASxα/p38α-SUMOylation/MK2 facilitates gastric cancer metastasis.2021Cell death & diseaseFree full text
  22. Bibliometric Evaluation of Publications (2000-2020) on the Prognosis of Gastric Cancer.2021Inquiry : a journal of medical care organization, provision and financingFree full text
All its trials on ClinicalTrials.gov, any status2
  1. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  2. Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GCStatus unknownNCT04638959Study siteStart 2019-09

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 29 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 9.6%.

Papers led
29
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 6620222023: 5520232024: 6620242025: 882025

11 hospitals in Shanghai for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology
Papers it led29
  1. Status of and factors influencing paternal fatigue in children with retinoblastoma: a cross-sectional study.2025BMC cancer
  2. Factors influencing delayed medical treatment in children with retinoblastoma: a qualitative study.2025BMC cancer
  3. Anxiety, depression and fear of disease progression among Chinese parents of children with retinoblastoma.2025BMC psychiatry
  4. Lactylation-boosted polycomb repression of KLF4 elicits glycolysis in retinoblastoma: A positive feedback circuit between histone modifications.2025Cancer letters
  5. Spatial Proteomic Analysis Highlights Molecular Reprogramming in Optic Nerve Invasive Retinoblastoma.2025Investigative ophthalmology & visual science
  6. Aurora A Kinase Inhibition Is Synthetic Lethal With the Activation of MYCN in Retinoblastoma.2025Investigative ophthalmology & visual science
  7. Increased clinical risk factors and absence of leucocoria in late-onset retinoblastoma: a comparative cohort study.2025The British journal of ophthalmology
  8. Effect of intra-arterial chemotherapy drug regimens on globe salvage outcomes of retinoblastoma patients.2025The British journal of ophthalmology
  9. Does vitreous haemorrhage and calcification lead to increased risk of enucleation in advanced retinoblastoma?2024Acta ophthalmologica
  10. Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management.2024Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
  11. Hemostatic effect of 3D-printed hip fixators in children with retinoblastoma after intra-arterial chemotherapy: a non-randomized controlled trial.2024Scientific reports
  12. Factors influencing parental fatigue in children with retinoblastoma based on the unpleasant symptoms theory.2024Scientific reports
  13. Risk factors for cataract in retinoblastoma management.2024The British journal of ophthalmology
  14. Correlating somatic copy number alteration in aqueous humour cfDNA with chemotherapy history, eye salvage and pathological features in retinoblastoma.2024The British journal of ophthalmology
  15. NSUN2-mediated m5 C RNA methylation dictates retinoblastoma progression through promoting PFAS mRNA stability and expression.2023Clinical and translational medicine
  16. Human Papillomavirus and Retinoblastoma: Evidence From a Systematic Review and Meta-analysis of Cross-Sectional Studies.2023International journal of public health
  17. The Use of rAAV2-RB1-Mediated Gene Therapy in Retinoblastoma.2023Investigative ophthalmology & visual science
  18. A novel MYCN-YTHDF1 cascade contributes to retinoblastoma tumor growth by eliciting m6A -dependent activation of multiple oncogenes.2023Science China. Life sciences
  19. Intravenous versus super-selected intra-arterial chemotherapy in children with advanced unilateral retinoblastoma: an open-label, multicentre, randomised trial.2023The Lancet. Child & adolescent health
  20. Contemporary Update of Retinoblastoma in China: Three-Decade Changes in Epidemiology, Clinical Features, Treatments, and Outcomes.2022American journal of ophthalmology
  21. Novel insights into RB1 mutation.2022Cancer letters
  22. Eye-Preserving Therapies for Advanced Retinoblastoma: A Multicenter Cohort of 1678 Patients in China.2022Ophthalmology
  23. Regulation of epigenetic homeostasis in uveal melanoma and retinoblastoma.2022Progress in retinal and eye research
  24. Monitoring Retinoblastoma by Machine Learning of Aqueous Humor Metabolic Fingerprinting.2022Small methods
  25. Risk factors for ophthalmic artery stenosis and occlusion in patients with retinoblastoma treated with intra-arterial chemotherapy.2022The British journal of ophthalmology
  26. Hope level and associated factors among parents of retinoblastoma patients during COVID-19 pandemic: a cross-sectional study.2021BMC psychiatry
  27. Single-cell transcriptome profiling reveals intratumoural heterogeneity and malignant progression in retinoblastoma.2021Cell death & disease
  28. Clinical characteristics and germline mutation spectrum of RB1 in Chinese patients with retinoblastoma: A dual-center study of 145 patients.2021Experimental eye research
  29. Xanthatin Selectively Targets Retinoblastoma by Inhibiting the PLK1-Mediated Cell Cycle.2021Investigative ophthalmology & visual science
Chinese-language papers (not in the count)1
  1. [Metachronous bilateral retinoblastoma: a case report].2024[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
Earlier papers (2016–2020)4
  1. LncRNA CANT1 suppresses retinoblastoma progression by repellinghistone methyltransferase in PI3Kγ promoter.2020Cell death & disease
  2. A novel LncRNA transcript, RBAT1, accelerates tumorigenesis through interacting with HNRNPL and cis-activating E2F3.2020Molecular cancer
  3. Dynamic chromosomal tuning of a novel GAU1 lncing driver at chr12p13.32 accelerates tumorigenesis.2018Nucleic acids research
  4. [Pay attention to the application of the international intraocular retinoblastoma classification and sequential multiple modality treatment].2017[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
All its trials on ClinicalTrials.gov, any status1
  1. A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of RetinoblastomaStatus unknownNCT04990271Study sitePhase 2Start 2021-07

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 16 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
16
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 1120222023: 4420232024: 3320242025: 552025

60 hospitals in Shanghai for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led16
  1. Tumor microenvironment-activated ROS enhancers for effective inhibition of osteosarcoma.2025BMC biotechnology
  2. Cancer-associated fibroblasts in osteosarcoma: key players in immune escape and targeted therapy.2025Frontiers in immunology
  3. Malignant transformation of craniofacial fibrous dysplasia: A clinicopathological, immunohistochemical and molecular analysis of 15 cases in one single institution.2025Journal of stomatology, oral and maxillofacial surgery
  4. Nanohydroxyapatite-Stabilized Pickering-Emulsion-Incorporated Hydrogel Prevents Postoperative Osteosarcoma Recurrence and Promotes Bone Repair.2025Nano letters
  5. Prognostic factors of head and neck osteosarcoma: A 10-year retrospective study from a single institute.2025Oral oncology
  6. Photothermal-Triggered Extracellular Matrix Clearance and Dendritic Cell Maturation for Enhanced Osteosarcoma Immunotherapy.2024ACS applied materials & interfaces
  7. Head and Neck Osteosarcoma: Perineural Invasion is Associated With Disease-Free Survival and Tumor Metastasis.2024Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  8. Real-world impact of chemotherapy on overall survival in craniomaxillofacial osteosarcoma.2024Journal of stomatology, oral and maxillofacial surgery
  9. DDRGK1 Enhances Osteosarcoma Chemoresistance via Inhibiting KEAP1-Mediated NRF2 Ubiquitination.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  10. EVI2B Is a Prognostic Biomarker and Is Correlated with Monocyte and Macrophage Infiltration in Osteosarcoma Based on an Integrative Analysis.2023Biomolecules
  11. Osteosarocma progression in biomimetic matrix with different stiffness: Insights from a three-dimensional printed gelatin methacrylamide hydrogel.2023International journal of biological macromolecules
  12. Secreted phosphoprotein 24 kD (Spp24) inhibits the growth of human osteosarcoma through the BMP-2/Smad signaling pathway.2023Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  13. Camouflage orthodontic treatment combined with genioplasty distraction osteogenesis for skeletal class II relationship secondary to osteosarcoma excision surgery.2022Journal of esthetic and restorative dentistry : official publication of the American Academy of Esthetic Dentistry ... [et al.]
  14. Ultrathin 2D Inorganic Ancient Pigment Decorated 3D-Printing Scaffold Enables Photonic Hyperthermia of Osteosarcoma in NIR-II Biowindow and Concurrently Augments Bone Regeneration.2021Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  15. Polydopamine-coated UiO-66 nanoparticles loaded with perfluorotributylamine/tirapazamine for hypoxia-activated osteosarcoma therapy.2021Journal of nanobiotechnology
  16. FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53.2021Oncogene
Chinese-language papers (not in the count)1
  1. [Clincopathological analysis of 171 patients with osteochondroma and malignant transformation in maxillofacial bone].2024Shanghai kou qiang yi xue = Shanghai journal of stomatology
Earlier papers (2016–2020)22
  1. Diffusion Kurtosis Imaging as a Prognostic Marker in Osteosarcoma Patients with Preoperative Chemotherapy.2020BioMed research international
  2. A population-based propensity-matched study of regional dissections in patients with metastatic osteosarcoma.2020Journal of orthopaedic surgery and research
  3. P-Glycoprotein Overexpression Is Associated With Cisplatin Resistance in Human Osteosarcoma.2019Anticancer research
  4. SNHG16 promotes osteosarcoma progression and enhances cisplatin resistance by sponging miR-16 to upregulate ATG4B expression.2019Biochemical and biophysical research communications
  5. HDAC2-mediated upregulation of IL-6 triggers the migration of osteosarcoma cells.2019Cell biology and toxicology
  6. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.2019Cell death & disease
  7. Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin.2019Clinical epigenetics
  8. Bone morphogenetic protein-2 promotes osteosarcoma growth by promoting epithelial-mesenchymal transition (EMT) through the Wnt/β-catenin signaling pathway.2019Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  9. Autophagy inhibition enhances celecoxib-induced apoptosis in osteosarcoma.2018Cell cycle (Georgetown, Tex.)
  10. CXCR1/Akt signaling activation induced by mesenchymal stem cell-derived IL-8 promotes osteosarcoma cell anoikis resistance and pulmonary metastasis.2018Cell death & disease
  11. Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma.2018Current drug targets
  12. MiR-127-3p inhibits cell growth and invasiveness by targeting ITGA6 in human osteosarcoma.2018IUBMB life
  13. Baicalin induces apoptosis in human osteosarcoma cell through ROS-mediated mitochondrial pathway.2018Natural product research
  14. The expression significance of serum MiR-21 in patients with osteosarcoma and its relationship with chemosensitivity.2017European review for medical and pharmacological sciences
  15. Chemotherapy in head and neck osteosarcoma: Adjuvant chemotherapy improves overall survival.2017Oral oncology
  16. Dryofragin inhibits the migration and invasion of human osteosarcoma U2OS cells by suppressing MMP-2/9 and elevating TIMP-1/2 through PI3K/AKT and p38 MAPK signaling pathways.2016Anti-cancer drugs
  17. Tectorigenin inhibits osteosarcoma cell migration through downregulation of matrix metalloproteinases in vitro.2016Anti-cancer drugs
  18. Post-operative hemimaxillectomy rehabilitation using prostheses supported by zygoma implants and remaining natural teeth.2016Clinics (Sao Paulo, Brazil)
  19. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3.2016Oncotarget
  20. Osteosarcoma of head and neck: A retrospective study on prognostic factors from a single institute database.2016Oral oncology
  21. Osteosarcoma of the Mandible: A Site-Specific Study on Survival and Prognostic Factors.2016The Journal of craniofacial surgery
  22. TIMP3 regulates osteosarcoma cell migration, invasion, and chemotherapeutic resistances.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 4 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 3320242025: 002025

21 hospitals in Shanghai for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

34 hospitals in Shanghai for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

9 hospitals in Shanghai for haemophilia A160 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 1 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 1.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

4 hospitals in Shanghai for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Shanghai for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Aneurysms in Takayasu's arteritis: a retrospective study of Chinese patients.2020Clinical and experimental rheumatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 4 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.4%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 222025

34 hospitals in Shanghai for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led no English-language PubMed papers on spinal muscular atrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Shanghai for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 2 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

12 hospitals in Shanghai for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

15 hospitals in Shanghai for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

26 hospitals in Shanghai for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. miR-200bc/429 cluster alleviates inflammation in IgA nephropathy by targeting TWEAK/Fn14.2017International immunopharmacology

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

6 hospitals in Shanghai for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led no English-language PubMed papers on Hirschsprung disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Shanghai for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)2
  1. A homozygous MITF mutation leads to familial Waardenburg syndrome type 4.2019American journal of medical genetics. Part A
  2. Genetic analysis of a Chinese family with members affected with Usher syndrome type II and Waardenburg syndrome type IV.2017International journal of pediatric otorhinolaryngology

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led 1 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 1.8%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

7 hospitals in Shanghai for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led 1 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 1.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Shanghai for Leber hereditary optic neuropathy32 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

上海交通大学医学院附属第九人民医院

Shanghai Ninth People's Hospital

上海

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Suzhou Ninth People's Hospital; Ninth People's Hospital of Chongqing; Chongqing Ninth People's Hospital; Suzhou Ninth People's Hospital Affiliated to Soochow University; Huangpu Branch of the Ninth People's Hospital; Hangzhou Ninth People's Hospital; Bethel Hospital; 上海第九人民医院

Suggest a correctionDownload the data